

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4958100

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CLEMENS DURR	01/30/2015
THOMAS HUBER	01/23/2015
JEAN-MICHEL RENE RONDEAU	02/06/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NOVARTIS PHARMA AG
<b>Street Address:</b>	LICHTSTRASSE 35
<b>City:</b>	BASEL
<b>State/Country:</b>	SWITZERLAND
<b>Postal Code:</b>	4056
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14940961
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	stephanie.geis@novartis.com
<b>Correspondent Name:</b>	STEPHANIE GEIS
<b>Address Line 1:</b>	NIBR
<b>Address Line 2:</b>	700 MAIN STREET
<b>Address Line 4:</b>	CAMBRIDGE, MASSACHUSETTS 02139
<b>ATTORNEY DOCKET NUMBER:</b>	PAT056506-US-NP
<b>NAME OF SUBMITTER:</b>	STEPHANIE GEIS
<b>SIGNATURE:</b>	/Stephanie Geis/
<b>DATE SIGNED:</b>	05/11/2018
<b>Total Attachments: 10</b>	
source=PAT056506_Inventors_NPHAG#page1.tif	
source=PAT056506_Inventors_NPHAG#page2.tif	
source=PAT056506_Inventors_NPHAG#page3.tif	
source=PAT056506_Inventors_NPHAG#page4.tif	

source=PAT056506\_Inventors\_NPHAG#page5.tif  
source=PAT056506\_Inventors\_NPHAG#page6.tif  
source=PAT056506\_Inventors\_NPHAG#page7.tif  
source=PAT056506\_Inventors\_NPHAG#page8.tif  
source=PAT056506\_Inventors\_NPHAG#page9.tif  
source=PAT056506\_Inventors\_NPHAG#page10.tif

**ASSIGNMENT**

This Assignment Agreement is entered into by and between:

Thomas HUBER	citizen of Switzerland	Novartis Pharma AG Postfach 4002 Basel Switzerland
Jean-Michel Rene RONDEAU	citizen of France	Novartis Pharma AG Postfach 4002 Basel CH
Clemens Dürr	citizen of Germany	Eimeldinger Weg 12/2 Weil am Rhein 79576 GERMANY

(hereinafter "Inventor(s)"), and **NOVARTIS PHARMA AG**, Lichtstrasse 35,4056 Basel, Switzerland, a company organized under the laws of Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS PHARMA AG is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS PHARMA AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

**Antibody Drug Conjugates**  
**[Patent Application reference: PAT056506-US-PSP]**

and filed in the \_\_\_\_\_ Office on \_\_\_\_\_, 20\_\_\_\_ and accorded Application Number \_\_\_\_\_ and/or filed as a PCT International Application on \_\_\_\_\_, 20\_\_\_\_ and accorded International Patent Application Number \_\_\_\_\_

PCT/\_\_\_\_\_ ; and/or filed in the United States Patent and Trademark Office on **November 14 , 2014** and accorded Application Number **62/079942**;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be

granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_.

BY \_\_\_\_\_ L.S.  
Thomas HUBER

Witnessed by:

\_\_\_\_\_  
Name:  
Address:

\_\_\_\_\_  
Name:  
Address:

Executed this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_.

BY \_\_\_\_\_ L.S.  
Jean-Michel Rene RONDEAU

Witnessed by:

\_\_\_\_\_  
Name:  
Address:

\_\_\_\_\_  
Name:  
Address:

Executed this 30<sup>th</sup> day of January, 2015.

BY *C. Diirr* L.S.  
Clemens Diirr

Witnessed by:

*Dr. Holger Rickardosen*  
Name:  
Address:  
EIMELDINGER WEG 12/11  
73576 WEIL AM RHEIN  
*H. Rickardosen*

*Dr. Christian Bischoff*  
Name: DR. CHRISTIAN BISCHOFF  
Address: Eimeldinger Weg 12/5  
D-79576 Weil am Rhein

NOVARTIS PHARMA AG

Executed this 14<sup>th</sup> day of February, 2015

BY [Signature] L.S.  
Name: Rob Heubersen  
Title: Authorized Signatory

Witnessed by:

[Signature]  
Name: Maria Storti  
Address: Lichtstrasse 35  
4056 Basel  
Switzerland

[Signature]  
Name: Silvia Aregger  
Address: Lichtstrasse 35  
4056 Basel  
Switzerland

BY [Signature] L.S.  
Name: GIULIA CECCARELLI  
Title: Authorized Signatory AUTHORIZED SIGNATORY

Witnessed by:

[Signature]  
Name: Maria Storti  
Address: Lichtstrasse 35  
4056 Basel  
Switzerland

[Signature]  
Name: Silvia Aregger  
Address: Lichtstrasse 35  
4056 Basel  
Switzerland

**ASSIGNMENT**

This Assignment Agreement is entered into by and between:

Thomas HUBER	citizen of Switzerland	Novartis Pharma AG Postfach 4002 Basel Switzerland
Jean-Michel Rene RONDEAU	citizen of France	Novartis Pharma AG Postfach 4002 Basel CH
Clemens Dürr	citizen of Germany	Eimeldinger Weg 12/2 Weil am Rhein 79576 GERMANY

(hereinafter "Inventor(s)"), and **NOVARTIS PHARMA AG**, Lichtstrasse 35,4056 Basel, Switzerland, a company organized under the laws of Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS PHARMA AG is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS PHARMA AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

**Antibody Drug Conjugates**  
**[Patent Application reference: PAT056506-US-PSP]**

and filed in the \_\_\_\_\_ Office on \_\_\_\_\_, 20\_\_\_\_ and accorded Application Number \_\_\_\_\_ and/or filed as a PCT International Application on \_\_\_\_\_, 20\_\_\_\_ and accorded International Patent Application Number \_\_\_\_\_



PCT/\_\_\_\_\_ ; and/or filed in the United States Patent and Trademark Office on **November 14 , 2014** and accorded Application Number **62/079942**;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be

granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 23 day of January, 2015.

BY [Signature] L.S.  
Thomas HUBER

Witnessed by:

[Signature]  
Name: Emile Popp  
Address: Novartis Pharma AG  
WSJ-155  
Postfach  
4002 Basel

[Signature]  
Name: Franciska Rindl  
Address: Novartis Pharma AG  
WSJ-155  
Postfach  
4002 Basel

Executed this 26 day of February, 2015.

BY [Signature] L.S.  
Jean-Michel Rene RONDEAU

Witnessed by:

[Signature]  
Name: JAVIER RAO  
Address: 3037-88 St  
Postfach  
9022 Basel

[Signature]  
Name: Ulrich Hainzel  
Address: 4037-88 St. 10-10  
4062 Basel

Executed this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_\_.

BY \_\_\_\_\_ L.S.  
Clemens Dürr

Witnessed by:

Name: \_\_\_\_\_  
Address: \_\_\_\_\_

Name: \_\_\_\_\_  
Address: \_\_\_\_\_

NOVARTIS PHARMA AG

Executed this 11<sup>th</sup> day of February, 2015.

BY [Signature] L.S.  
Name: Peter Halberisen  
Title: Authorized Signatory

Witnessed by:

[Signature]  
Name: MARIA STADLER  
Address: Lichtstrasse 35  
4056 Basel  
Switzerland

[Signature]  
Name: Silvia Aregger  
Address: Lichtstrasse 35  
4056 Basel  
Switzerland

BY [Signature] L.S.  
Name: GIULIA CECARELLI  
Title: Authorized Signatory

Witnessed by:

[Signature]  
Name: MARIA STADLER  
Address: Lichtstrasse 35  
4056 Basel  
Switzerland

[Signature]  
Name: Silvia Aregger  
Address: Lichtstrasse 35  
4056 Basel  
Switzerland